Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Inovio Biomedical Partner Tripep Provides Update on its Hepatitis C DNA Vaccine Program
June 6th, 2007
Inovio Biomedical Corp. (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that its partner, Tripep AB of Sweden, has provided an update regarding its application to the Swedish Medical Products Agency (MPA) to initiate a Phase I clinical trial for its proprietary DNA vaccine, ChronVac-C(R), administered using Inovio's MedPulser(R) DNA Delivery System. Tripep announced it intends to file with the MPA a modified application designed to permit clinical testing of ChronVac-C(R) in subjects already infected with hepatitis C virus instead of healthy volunteers, as per the...
Source: Vaccine Weekly (2007-06-06)
|
